Vivistim

What Vivistim does

Vivistim is the commercial product brand of MicroTransponder, Inc. (recently rebranded to Mobia Medical in February 2026), an Austin, Texas-based privately held medical device company with 51-100 employees. The company develops and markets the Vivistim Paired VNS System, an FDA-approved implantable vagus nerve stimulation device designed to improve upper-limb motor function in chronic ischemic stroke survivors with moderate to severe arm impairment. The system pairs left vagus nerve stimulation with task-specific rehabilitation therapy (typically 90-minute clinic sessions three times per week for a minimum of six weeks) plus patient self-activated home sessions using a magnet up to eight times per day, and is MRI-conditional under specified safety guidelines.

The core technology is anchored by FDA PMA P210007 approval and a Breakthrough Device designation, with clinical efficacy supported by the VNS-REHAB pivotal trial published in the Lancet (2021), which demonstrated 2-3 times greater improvement in hand and arm function compared to intensive therapy alone, with 98% patient satisfaction and durable benefit sustained over 2-3 year follow-up periods. The system consists of an implantable pulse generator (IPG), lead, wireless tablet, and patient magnet accessory.

Vivistim generates revenue primarily through a hardware-plus-services model: the implantable device and procedure, reimbursed at an average of $45,000 per case under a new Medicare payment classification effective January 1, 2026, plus associated in-clinic rehabilitation therapy services delivered at certified stroke centers. The go-to-market is enterprise field sales targeting implanting physicians and stroke rehabilitation hospitals nationwide, supplemented by patient-direct digital marketing (eligibility surveys, testimonials, webinars) and professional education channels. Geographic operations are currently US-only.

Name

Vivistim

Legal name

MicroTransponder, Inc.

Website

https://vivistim.com

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Vivistim, a product brand of Austin-based MicroTransponder (now Mobia Medical), markets an FDA-approved implantable vagus nerve stimulation device paired with rehabilitation therapy to improve upper-limb motor function in chronic ischemic stroke survivors, distributed through a US network of certified implanting physicians at stroke centers.

Ownership category

akta.pro rank

Product category

Implantable Neurostimulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Ambulatory Health Care Services (6219)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industries

Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK), Post-Acute & Transitional Care Virtual Platforms (SNF/home health coordination) (HLALABAG)

Keywords

• Implantable neurostimulation devices
• Vagus nerve stimulation
• Stroke rehabilitation therapy
• Neuromodulation medical devices
• Post-stroke recovery

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Vivistim Procedure: CMS assigned the Vivistim procedure to a new Medicare payment classification with an average payment of $45,000, effective January 1, 2026. Revenue is generated through the implantable device procedure combined with associated therapy services.
2. Clinical Therapy Services: Revenue generated from therapy sessions administered at stroke rehabilitation centers, with sessions running 90 minutes three times per week for a minimum of six weeks.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Vivistim sells the FDA-approved Vivistim Paired VNS System, an implantable vagus nerve stimulation device that is paired with rehabilitation therapy to improve hand and arm function in chronic ischemic stroke survivors with moderate to severe upper limb impairment. The system consists of an implantable pulse generator, lead, wireless tablet, and patient magnet, and is prescribed and implanted by trained physicians at stroke centers, with therapy administered by certified occupational and physical therapists in clinic and self-activated by patients at home.

Product overview

Vivistim offers a single core product: the Vivistim Paired VNS System, an FDA-approved breakthrough medical device. This first-of-its-kind technology uses vagus nerve stimulation during rehabilitation therapy and daily activities to help chronic ischemic stroke survivors improve hand and arm function by enhancing neuroplasticity. The system includes an implantable pulse generator (IPG), lead, wireless tablet (WT), and patient magnet (SAPS) that work together during clinical therapy sessions and self-activated home use.

Differentiator

Problem solved

Functional benefit

Products and services

• Vivistim Paired VNS System

Quantifiable outcome

• 2-3 times more hand and arm function improvement compared to intense therapy alone
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Adler Aphasia CentercoreStrategic or Co-development Partner · 14 May 2026Adler Aphasia Center hosted a Stroke Recovery Event in Maywood, New Jersey on May 14th, featuring over 25 organizations including Vivistim. The nonprofit, founded in 2003, operates three facilities in New Jersey and serves approximately 70,000 people living with aphasia in the state. Vivistim participated as a vendor providing information about stroke recovery programs.
• Morristown Medical CentercoreStrategic or Co-development PartnerMedical professionals from Morristown Medical Center presented at the Adler Aphasia Center Stroke Recovery Event, providing education about stroke recovery and treatment options including Vivistim.
• Overlook Medical CentercoreStrategic or Co-development PartnerMedical professionals from Overlook Medical Center presented at the Adler Aphasia Center Stroke Recovery Event, providing education about stroke recovery and treatment options including Vivistim.
• CMS (Centers for Medicare & Medicaid Services)coreOthersCMS assigned Vivistim procedure to a new Medicare payment classification with an average payment of $45,000, effective January 1, 2026, enhancing access to therapy for Medicare beneficiaries.
• Leading Stroke Care OrganizationsminorGTM or Marketing PartnerVivistim partners with and supports leading organizations advancing stroke care, as evidenced by logo partnerships displayed on their website.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• LivaNova: Markets the Vagus Nerve Stimulation (VNS) Therapy system, an implantable pulse generator originally developed for drug-resistant epilepsy. Uses the identical core modality (implantable VNS) and overlapping neurostimulation manufacturing and physician network, making it the most direct technology peer.
• Electrocore: Markets gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for migraine, cluster headache, and post-traumatic stress. Uses the same vagus nerve stimulation mechanism as Vivistim but with a non-invasive delivery, providing a potential substitute therapy for certain stroke indications.
• Helius Medical Technologies: Develops the PoNS (Portable Neuromodulation Stimulator) device, an FDA-authorized neurostimulation product indicated for stroke-related gait and balance deficits. Direct competitor in the stroke neurostimulation rehabilitation market, addressing the same patient population and physician specialty.

Broad incumbents

• Boston Scientific: Markets the Vercise DBS systems and a broad neuromodulation portfolio. A diversified incumbent with deep neuroscience commercial channels that could leverage existing infrastructure to enter adjacent neurostimulation indications such as stroke.
• Axonics: Markets sacral and pudendal neuromodulation systems for incontinence. A pure-play implantable neurostimulator with similar size, regulatory pathway, and commercial dynamics to Vivistim, making it a strong comparable for valuation and commercialization benchmarking.
• Medtronic: Operates the VNS Therapy franchise (acquired via Cyberonics) and the Activa Deep Brain Stimulation (DBS) portfolio. As the dominant neurostimulation incumbent with established physician relationships, manufacturing scale, and R&D depth, Medtronic is the most capable potential competitor in stroke neurostimulation.
• Inspire Medical Systems: Markets the Inspire hypoglossal nerve stimulation implant for obstructive sleep apnea. A successful pure-play implantable neurostimulator company whose commercial playbook, payer engagement approach, and implanting physician network model are highly relevant comparables for Vivistim's commercialization.
• Abbott: Sells the Infinity DBS, Proclaim DRG, and Proclaim XR spinal cord stimulation systems. Has a large neuromodulation commercial footprint that could readily expand into stroke indications and represents a competitive threat to Vivistim's growth.

Emerging players

• Bionik Laboratories: Develops robotic rehabilitation technologies (InMotion ARM) for stroke and other neurological conditions. Targets the same stroke rehabilitation patient population and competes for share of therapy budgets within stroke centers, though through robotic rather than neurostimulation means.
• MindMaze: Develops digital neurotherapeutics and gamified rehabilitation platforms for stroke and brain injury recovery. While not an implant, it targets the same post-stroke upper limb and motor function rehabilitation market with a non-invasive digital approach that could serve as an alternative or adjunct to Vivistim therapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/VivistimSystem
• Facebookfacebook.com/Vivistim
• LinkedInlinkedin.com/company/microtransponder

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivistim